drugset
drugset / Trial / NCT03550950

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

NCT03550950 ↗

Phase 1 Completed 48 enrolled Janssen Research & Development, LLC
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of JNJ-64232025 following single ascending intravenous (IV) study intervention administrations and a single subcutaneous (SC) intervention administration in healthy participants.

Timeline

Start
2018-06-01
Primary completion
2019-02-05
Completion
2019-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject JNJ-64232025 Unknown — Intravenous

Indications

No indication recorded.